Abstract:Background: At present, COVID-19 is the most serious threat to global public health. It is important to understand COVID-19 from different perspectives. Evidence is needed to determine whether there are differences in the clinical characteristics of COVID-19 patients as the SARS-CoV-2 virus continues to circulate in the population.Methods: This is a retrospective, multi-center cohort study. All adult cases with laboratory-confirmed COVID-19 from four hospitals in Zhejiang, China were enrolled in this study. Based on epidemiological history, patients were clustered into 3 groups. They included first-generation patients who had a clear travel history to Hubei within 14 days before disease onset; second generation patients who had a clear contact history with first-generation patients; third-generation patients who had a clear contact history with second-generation patients. Demographic, clinical characteristics, radiological features, laboratory data, clinical outcomes, and duration of viral shedding were then analyzed.Findings: Total of 171 patients with COVID-19 (aged 50.5±15.2 years, 92 males (53.8)) were enrolled. Third generation patients were older ( P <0.001), had more coexisting conditions ( P =0.013), a higher level of urea nitrogen ( P <0.05) and significantly higher CURB-65 scores ( P =0.004) compared to the other two groups. At 7±1 days from illness onset, white blood cell counts decreased in 26.9% of patients, lymphocyte counts decreased in 50.3% of patients, and platelet counts decreased in 11.4% of patients. Lung CT scans indicated that 66.1% of patients had a wide range of lesions that involved 4-5 pulmonary lobes. Third generation patients had lower lymphocyte and platelet levels ( P =0.007), higher C-reactive protein ( P =0.007) and D-dimer levels ( P =0.002), and more lesions involving the pulmonary lobes as determined by lung CT scans ( P <0.001). The proportion of third-generation patients who developed severe illness ( P <0.001), critical illness ( P <0.001) and received endotracheal intubation ( P =0.002) were significantly higher compared to the other two groups. No significant differences were observed between the three groups for the mean time from onset to severe or critical illness, distribution of endotracheal intubation and ECMO treatment, SARS-CoV-2 RNA negative conversion in the respiratory tract.Interpretation: Third generation patients were older, had more underlying comorbidities and had a higher proportion of severe or critical illness compared to first and second-generation patients. Baseline characteristics and clinical procedures in first- and second-generation patients were similar. We did not observe evidence of decreased virulence after the SARS-CoV-2 virus had passed through the population in Zhejiang, China.Funding Statement: This work was supported by a grant for COVID-19 from Jiaxing Science and Technology Bureau (2020GZ30001) and a grant from the National Natural Science Foundation of China (81971897). The research funding was provided to Dr. Hua Zhou.Declaration of Interests: All authors declare no conflicts of interest.Ethics Approval Statement: The study was approved by the Research Ethics Commission of The First Affiliated Hospital, School of Medicine, Zhejiang University (IIT20200129A), and supported by the Research Ethics Commissions of the other three hospitals. Due to the urgency to collect data on this emerging pathogen, the requirement for informed consent was waived by the Ethics Commission.

Human-to-human transmission of 2019-novel coronavirus (2019-nCoV)

Evidence and characteristics of human-to-human transmission of SARS-CoV-2

Transmission Dynamics of 2019 Novel Coronavirus (2019-Ncov)

Genomic Characterisation and Epidemiology of 2019 Novel Coronavirus: Implications for Virus Origins and Receptor Binding

Genomic epidemiology reveals early transmission of SARS-CoV-2 and mutational dynamics in Nanning, China

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia

The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020

Genomic Elucidation of a COVID-19 Resurgence and Local Transmission of SARS-CoV-2 in Guangzhou, China.

Epidemiological, Clinical, and Virological Characteristics of 465 Hospitalized Cases of Coronavirus Disease 2019 (COVID-19) from Zhejiang Province in China

Clinical characteristics of 2019 novel coronavirus infection in China

Clinical Characteristics of COVID-19 Patients at Different Epidemic Stages in Zhejiang, China

Epidemiological, Clinical and Virological Characteristics of 74 Cases of Coronavirus-Infected Disease 2019 (COVID-19) with Gastrointestinal Symptoms

Household Transmission of SARS-CoV-2, Zhuhai, China, 2020

A Family Cluster of SARS-CoV-2 Infection Involving 11 Patients in Nanjing, China

Pattern of early human-to-human transmission of Wuhan 2019-nCoV

Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin

Modes of Contact and Risk of Transmission in COVID-19: A Prospective Cohort Study 4950 Close Contact Persons in Guangzhou of China

Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China

Genomic surveillance of a resurgence of COVID-19 in Guangzhou, China

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Clinical Characteristics of Patients Infected with the Novel 2019 Coronavirus (Sars-Cov-2) in Guangzhou, China.